The adjusted Global Antiphospholipid Syndrome Score (aGAPSS), which incorporates independent CVD risk factors along with the serum aPL profile, has been proposed as a tool in predicting CVD risk in patients with SLE [75]. The gene discussed is FASLG; the disease is systemic lupus erythematosus.